OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 feb 2009 - 16:51
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus signs service contract with Galapagos
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), the drug delivery company, announces today that it has signed a pharmaceutical development contract with a new client, Galapagos N.V. (Euronext: GLPG). The undisclosed contract value significantly contributes to OctoPlus’ annual revenues.
Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos’ Phase II study of Nanocort®, a liposome formulation of prednisolone. OctoPlus has progressed the scale-up and robustness of the production process of this complex liposomal product.
Datum laatste update: 30 december 2025